title: Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.
abstract: •Case describes a response to sunitinib in clear cell ovarian cancer.•Discussion of unique molecular characteristics of clear cell ovarian cancers•Practical points regarding dosing and toxicity when using sunitinib discussed.
authors.affiliation: Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Alifrangis
authors.affiliation: Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom.
authors.forename: A
authors.initials: A
authors.lastname: Thornton
authors.affiliation: Dept. of Gynaecology, Imperial College London, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Fotopoulou
authors.affiliation: Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom; Division of Cancer, Imperial College London, United Kingdom.
authors.forename: J
authors.initials: J
authors.lastname: Krell
authors.affiliation: Dept. of Medical Oncology, Hammersmith Hospital, United Kingdom; Division of Cancer, Imperial College London, United Kingdom.
authors.forename: H
authors.initials: H
authors.lastname: Gabra
keywords: Clear cell; Drug resistance; Targeted therapy